Document Detail


Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
MedLine Citation:
PMID:  19308291     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Mutational changes coupled with endocrine, paracrine, and/or autocrine signals regulate cell division during carcinogenesis. The hormone signals remain undefined, although the absolute requirement in vitro for fetal serum indicates the necessity for a fetal serum factor(s) in cell proliferation. Using prostatic cancer cell (PCC) lines as a model of cancer cell proliferation, we have identified the fetal serum component activin A and its signaling through the activin receptor type II (ActRII), as necessary, although not sufficient, for PCC proliferation. Activin A induced Smad2 phosphorylation and PCC proliferation, but only in the presence of fetal bovine serum (FBS). Conversely, activin A antibodies and inhibin A suppressed FBS-induced PCC proliferation confirming activin A as one of multiple serum components required for PCC proliferation. Basic fibroblast growth factor was subsequently shown to synergize activin A-induced PCC proliferation. Inhibition of ActRII signaling using a blocking antibody or antisense-P decreased mature ActRII expression, Smad2 phosphorylation, and the apparent viability of PCCs and neuroblastoma cells grown in FBS. Suppression of ActRII signaling in PCC and neuroblastoma cells did not induce apoptosis as indicated by the ratio of active/inactive caspase 3 but did correlate with increased cell detachment and ADAM-15 expression, a disintegrin whose expression is strongly correlated with prostatic metastasis. These findings indicate that ActRII signaling is required for PCC and neuroblastoma cell viability, with ActRII mediating cell fate via the regulation of cell adhesion. That ActRII signaling governs both cell viability and cell adhesion has important implications for developing therapeutic strategies to regulate cancer growth and metastasis.
Authors:
Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neoplasia (New York, N.Y.)     Volume:  11     ISSN:  1476-5586     ISO Abbreviation:  Neoplasia     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-24     Completed Date:  2009-05-12     Revised Date:  2013-06-12    
Medline Journal Info:
Nlm Unique ID:  100886622     Medline TA:  Neoplasia     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  365-76     Citation Subset:  IM    
Affiliation:
Section of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin, Veterans Administration Hospital, Madison, WI 53705, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins / metabolism
Activin Receptors, Type II / metabolism*
Activins / metabolism*
Cell Adhesion / physiology
Cell Line, Tumor
Cell Survival / physiology
Epithelial Cells / cytology,  metabolism*
Humans
Immunoblotting
Male
Membrane Proteins / metabolism
Neuroblastoma / metabolism
Prostatic Neoplasms / metabolism*
Signal Transduction / physiology*
Chemical
Reg. No./Substance:
0/Membrane Proteins; 0/activin A; 104625-48-1/Activins; EC 2.7.11.30/Activin Receptors, Type II; EC 2.7.11.30/activin receptor type II-A; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/ADAM15 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer...
Next Document:  NHERF-1: modulator of glioblastoma cell migration and invasion.